Pancreatic Cancer Research

ResearcherDartmouth CollegeActive in the last 2 years

Christine Alewine

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1661-0957; OpenAlex author ID A5026706379; NIH RePORTER profile ID 14280079. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 1, last author 6)
Trials
2 (principal investigator on 2)
Grants
4
Labs led
1
Collaborators
26
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper, 1 trial · 2017: none · 2018: none · 2019: 1 trial · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: none · 2024: 2 papers, 2 grants · 2025: 1 paper, 2 grants · 2026: 1 paper

Papers 11

  1. Basal Marker ΔNp63α Is Enriched in Pancreatic Cancer Metastases but Not in Primary Tumors Post-Chemotherapy. Last author DOI 10.1002/cam4.72322↗
  2. Controlled Self-Immolative Release of β-Lapachone via an Optimized para-Hydroxybenzyl Linker for Targeted Pancreatic Cancer Therapy. Co-author DOI 10.1021/jacs.5c17598↗
  3. Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization. Last author DOI 10.1096/fj.202400446r↗
  4. Macrophages Under the Influence of Tumor Mesothelin Weaken Host Defenses against Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-23-4036↗
  5. Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci. Last author DOI 10.1002/cac2.12243↗
  6. Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment. Last author DOI 10.1016/j.tranon.2022.101440↗
  7. Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14174209↗
  8. Molecular mediators of peritoneal metastasis in pancreatic cancer. Last author DOI 10.1007/s10555-020-09924-4↗
  9. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-2586↗
  10. Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. First author DOI 10.1007/s12094-015-1459-8↗
  11. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-015-2788-6↗

Trials 2

  1. Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Ot… Principal investigator NCT04034238↗
  2. Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancre… Principal investigator NCT02810418↗

Grants 4

  1. Precision Therapy to Target Pancreatic Ductal Adenocarcinoma ZIABC011652↗
  2. Clinical Support ZIEBC011653↗
  3. First in Human Trials of ProAgio, a Cytotoxin ZIABC011886↗
  4. Rare Exocrine Tumors of the Pancreas ZIABC012041↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Leela Rani Avula · 2 shared papers, 2020–2024 · strength 0.41
  2. Nebojša Skorupan · 2 shared papers, 2022 · strength 0.40
  3. Daniel H. Ryan · 1 shared paper, 2026 · strength 0.33
  4. Yuuki Ohara · 1 shared paper, 2026 · strength 0.33
  5. Jian Xu · 1 shared paper, 2022 · strength 0.26
  6. Gonçalo J. L. Bernardes · 1 shared paper, 2025 · strength 0.25
  7. Julie B. Becher · 1 shared paper, 2025 · strength 0.25
  8. Theressa Ewa · 1 shared paper, 2024 · strength 0.22
  9. Brendan L. Hagerty · 1 shared paper, 2020 · strength 0.19
  10. William Douglas Figg · 2 shared papers, 2016–2020 · strength 0.18
  11. Xianyu Zhang · 1 shared paper, 2022 · strength 0.17
  12. Raffit Hassan · 1 shared paper, 2020 · strength 0.10
  13. Jane B Trepel · 1 shared paper, 2020 · strength 0.10
  14. Ira Pastan · 1 shared paper, 2020 · strength 0.10
  15. Zishuo I. Hu · 1 shared paper, 2020 · strength 0.10
  16. Julius Strauss · 1 shared paper, 2016 · strength 0.08
  17. Austin G. Duffy · 1 shared paper, 2016 · strength 0.08
  18. Rachna T. Shroff · 1 shared paper, 2015 · strength 0.04
  19. Milind M. Javle · 1 shared paper, 2015 · strength 0.04
  20. James L. Abbruzzese · 1 shared paper, 2015 · strength 0.04
  21. Huamin Wang · 1 shared paper, 2015 · strength 0.04
  22. Robert A. Wolff · 1 shared paper, 2015 · strength 0.04
  23. Alison P. Klein · 1 shared paper, 2015 · strength 0.04
  24. David R. Fogelman · 1 shared paper, 2015 · strength 0.04
  25. Luis Alberto Diaz · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.